Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
CJC-1295
Also known as: CJC-1295 DAC, CJC-1295 No DAC, Modified GRF 1-29, Mod GRF 1-29, Drug Affinity Complex
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with enhanced stability and a longer half-life than native GHRH. The DAC (Drug Affinity Complex) version binds to albumin, extending its half-life to approximately 6-8 days, while CJC-1295 without DAC (Mod GRF 1-29) has a half-life of roughly 30 minutes. Both versions stimulate sustained GH release and elevated IGF-1 levels.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 863288-34-0 |
| Molecular Formula | C152H252N44O42 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
CJC-1295 binds to the GHRH receptor on pituitary somatotrophs, stimulating the synthesis and secretion of growth hormone. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) protect against enzymatic degradation by DPP-IV. The DAC version forms a covalent bond with serum albumin via a reactive succinimide linker, greatly prolonging its circulating half-life and enabling less frequent dosing.
Dosing Research
CJC-1295 with DAC is typically dosed at 1-2 mg subcutaneously once or twice per week. CJC-1295 without DAC (Mod GRF 1-29) is commonly used at 100-300 mcg subcutaneously 2-3 times per day, often combined with a GHRP. Cycles of 8-12 weeks are standard.
Side Effects & Risks
Side effects may include flushing, headache, dizziness, and injection site reactions. Water retention and transient hypotension have been reported. Prolonged GH elevation from the DAC version may carry a theoretical risk of acromegalic-like effects with chronic use.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.